Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
Golden, Colorado, Oct. 04, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer, today announces the filing of a Form S-4 with the Securities and Exchange Commission requisite to complete the previously announced merger between the Company and IMAC Holdings, Inc. (NASDAQ:BACK)(“IMAC”)(the “Merger”). Upon regulatory approval, Theralink and IMAC expect to complete the Merger by the end of the current quarter.
Related news for (THER)
- Theralink announces groundbreaking RPPA study by partner GMU – reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
- Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
- Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
- Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer